Biotech Values

[DewDiligence]

Matt Herper’s write-up on AMGN’s injunction against Praluent; note mention of TRCA-INSM precedent, which dates back a decade (#msg-17647337):

http://www.forbes.com/sites/matthewherper/2017/01/06/could-amgens-patent-victory-be-bad-for-medicine/#69d6a30965fc

My brief rejoinder:

Thx,Matt.TRCA-INSM is direct precdnt,but their 2 drugs were probably more similar than Repatha/Praluent,so $AMGN injunctn harder2justfy,IMO. https://t.co/VFrIor9p5m

— Roy Friedman (@DewDiligence) January 6, 2017

.